全文获取类型
收费全文 | 4300篇 |
免费 | 353篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 142篇 |
妇产科学 | 50篇 |
基础医学 | 267篇 |
口腔科学 | 196篇 |
临床医学 | 521篇 |
内科学 | 499篇 |
皮肤病学 | 181篇 |
神经病学 | 21篇 |
特种医学 | 52篇 |
外科学 | 317篇 |
综合类 | 519篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 281篇 |
眼科学 | 76篇 |
药学 | 1392篇 |
2篇 | |
中国医学 | 95篇 |
肿瘤学 | 77篇 |
出版年
2024年 | 3篇 |
2023年 | 51篇 |
2022年 | 74篇 |
2021年 | 148篇 |
2020年 | 158篇 |
2019年 | 154篇 |
2018年 | 171篇 |
2017年 | 155篇 |
2016年 | 143篇 |
2015年 | 153篇 |
2014年 | 245篇 |
2013年 | 449篇 |
2012年 | 281篇 |
2011年 | 257篇 |
2010年 | 183篇 |
2009年 | 201篇 |
2008年 | 193篇 |
2007年 | 168篇 |
2006年 | 179篇 |
2005年 | 137篇 |
2004年 | 134篇 |
2003年 | 143篇 |
2002年 | 125篇 |
2001年 | 93篇 |
2000年 | 74篇 |
1999年 | 65篇 |
1998年 | 52篇 |
1997年 | 50篇 |
1996年 | 64篇 |
1995年 | 42篇 |
1994年 | 40篇 |
1993年 | 41篇 |
1992年 | 34篇 |
1991年 | 31篇 |
1990年 | 25篇 |
1989年 | 37篇 |
1988年 | 21篇 |
1987年 | 29篇 |
1986年 | 15篇 |
1985年 | 23篇 |
1984年 | 26篇 |
1983年 | 17篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 15篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 6篇 |
1975年 | 4篇 |
排序方式: 共有4763条查询结果,搜索用时 31 毫秒
1.
The research and development of penicillin started with difficulty before 1949 and achieved certain results. In 1951, after the founding of the People's Republic of China, Zhang Weishen, as the only Chinese scientist who had been trained and worked in a penicillin research and development center in the United States for many years, overcame many difficulties and returned to China. In 1953, with the efforts of Zhang Weishen and his colleagues, China realized the industrialized production of penicillin, alleviating the urgent needs of the masses. Antibiotics has also become the first discipline to achieve major scientific and technological achievements after the founding of the New China. In the mid-1950s, the technical breakthrough in the localization of lactose substitutes marked the localization of the raw materials of the penicillin-producing culture medium, which paved the way for the industrialized production of penicillin with Chinese characteristics. Antibiotics have become one of the most widely used and affordable drugs for hundreds of millions of patients in China, and China has since ended the humiliating history of the “Sick Man of East Asia". 相似文献
2.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
3.
P. Van Camp L. Verstraete B. Van Loon J. Scheerlinck E. Nout 《International journal of oral and maxillofacial surgery》2021,50(5):643-648
This study was undertaken to evaluate the infection rate following orthognathic surgery and to identify possible risk factors. A retrospective study was conducted. Patients undergoing orthognathic surgery from August 1, 2017 to July 31, 2018 were included. The outcome variable was surgical site infection (SSI). All data were analysed with respect to demographics and procedure specifications. A total of 137 patients (mean age 28.5 ± 12.69 years) were included in this study, of whom 20 (14.6%) developed a SSI. The only risk factor identified was the type of surgery: those undergoing mandibular osteotomies (in bilateral sagittal split osteotomy (BSSO) or bimaxillary osteotomies) were far more likely to develop infections. Third molar teeth were removed during orthognathic surgery in 28.5% of the procedures, and a genioplasty was performed in 10.9%. Removal of osteosynthesis material because of infectious reasons was necessary in 10.2% of patients, with a strong association to previous SSI. In conclusion, this study showed an infection rate of 14.6% with no link to any demographic risk factor. Neither the simultaneous removal of third molar teeth nor genioplasty was found to be a risk factor for SSI. For literature comparison purposes, there is a clear need for the international guidelines defining SSI to be used. 相似文献
4.
5.
6.
7.
8.
9.
10.